box" warning describing the cardiovascular risks of stimulant drugs used to treat attention deficit-hyperactivity disorder (ADHD). This action was unexpected, largely because the FDA had not requested a review of current labeling for this class of drugs; it had merely asked for recommendations of approaches to studying the cardiovascular risks associated with these drugs. The committee, however, decided to take an independent course. As a consultant to this committee, I introduced two motions, one recommending the black-box warning and the other proposing the development of a guide for patients, which was approved by a vote of 15 to 0. The guides are handouts that are required to be provided at the time prescriptions are dispensed; they contain information, written in nontechnical language, about the potential hazards of the medication.
The drugs under review were primarily amphetamines (Adderall and other brands) and methylphenidate (Ritalin, Concerta, and other brands). These agents are closely related members of the class of sympathomimetic amines, the structures of several of which are shown in the diagram. These compounds exert potent stimulant effects on the cardiovascular and central nervous systems. One of the oldest such agents, methamphetamine, was originally synthesized in 1891 and first widely used during World War II in Nazi Germany to enhance the ability of Luftwaffe pilots to stay alert during extended hours of combat. Medical use of this agent is now limited, but illicit use has grown rapidly and now represents an increasing public health problem. When smoked or injected intravenously, methamphetamine ("speed") is associated with hyperthermia, rhabdomyolysis, myocardial infarction, stroke, and sudden death -effects well known to coroners in regions of the United States where abuse is common. Beginning in the 1950s, the stereoisomer dextroamphetamine and related agents were introduced as appetite suppressants.
ADHD is a disorder common-
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ly diagnosed in school-age boys (less commonly in girls) and is characterized by increased activity, an inability to concentrate, and poor school performance. The effectiveness of stimulants in treating ADHD has been well documented in randomized clinical trials. Amphetamines and amphetamine-like stimulants were introduced to treat ADHD in the 1950s, but the frequency of this diagnosis and the use of stimulants to treat it have accelerated enormously in recent years. The FDA advisory committee heard testimony indicating that 2.5 million children now take stimulants for ADHD, including nearly 10 percent of all 10-year-old boys in the United States. 1 The committee also learned that the use of these agents is much less prevalent in European countries, where the diagnosis of ADHD is relatively uncommon. Even more strikingly, 1.5 million adults now take such stimulants on a daily basis, with 10 percent of users older than 50 years of age. The diagnosis of "adult" ADHD is a relatively recent phenomenon and has resulted in the most rapid growth in the use of such agents. 1 The concern of the advisory committee reflected several considerations. The cardiovascular effects of the sympathomimetic amines have been thoroughly described in the medical literature. These agents substantially increase the heart rate and blood pressure. In a placebo-controlled trial, mixed amphetamine salts (Adderall) administered to adults increased systolic blood pressure by about 5 mm Hg; similar effects were found with methylphenidate formulations. 2 Blood-pressure changes of this magnitude, particularly during long-term therapy, are known to increase morbidity and mortality. In 2005, a separate FDA advisory committee that I chaired concluded that bloodpressure changes represented such a reliable predictor of cardiovascular outcomes that class labeling would be appropriate in most cases. 3 The increases in heart rate induced by sympathomimetic agents also have well-described adverse cardiovascular effects. The administration of these drugs produces persistent increases in heart rate, inducing chronic heart failure in animal models of dilated cardiomyopathy.
A review of the regulatory history of this class of drugs also helps to explain why the advisory committee took decisive action. The dietary supplement ephedra, sometimes called ma huang, contains two alkaloids, ephedrine Similar regulatory actions have been proposed for phenylpropanolamine (PPA), another closely related sympathomimetic amine (see diagram). On December 22, 2005, the FDA issued a notice of "proposed rulemaking for overthe-counter nasal decongestant and weight control products" containing PPA. The notice called for a public comment period until March 22, 2006, after which the FDA would undertake regulatory action that would probably include banning the use of the agent in over-the-counter preparations. The FDA's action followed many years of concern about the potential of PPA products to cause hemorrhagic stroke. Six years ago, a case-control study published in the Journal reported a 16-fold increase in the risk of stroke among women taking PPA for appetite suppression. 5 Briefing documents prepared for the February 9 advisory-committee meeting described cases of myocardial infarction, stroke, and sudden death in children and adults taking ADHD stimulants. 1 These narratives were derived from the FDA's Adverse Event Reporting System (AERS), a database containing reports of adverse events submitted by health care providers. The AERS is a voluntary reporting system that has been criticized because only 1 to 10 percent of serious adverse events are actually reported, limiting the database's usefulness for identifying emerging drug hazards. The drug-related events reviewed by the committee included 25 cases of sudden death in children or adults (see table) , some with evidence on autopsy of undiagnosed congenital heart disease, such as hypertrophic obstructive cardiomyopathy. The physiology of this condition renders patients particularly vulnerable to the adverse effects of sympathomimetic drugs, because such agents increase contractility, thereby increasing the pressure gradient in the left ventricular outflow tract. Many additional cases of major adverse cardiovascular events, including myocardial infarction, stroke, and serious arrhythmias, were reviewed by the committee. However, the documentation of cases was frequently incomplete, and neither the FDA reviewers nor the committee considered the AERS data to be definitive. Despite the difficulty of interpreting these data, the advisory committee acted preemptively to recommend strong regulatory action. The majority of the group accepted my argument that the propensity of sympathomimetic agents to raise blood pressure and heart rate, the history of serious adverse effects associated with two members of the class (ephedra and PPA), and the rapid increase in exposure, particularly among adults, warranted strong and immediate action. Although the committee recognized that there are important potential benefits of these drugs for certain highly dysfunctional children, we rejected the notion that the administration of potent sympathomimetic agents to millions of Americans is appropriate. We sought to emphasize more selective and restricted use, while increasing awareness of potential hazards. We argued that the FDA should act soon, and decisively. 
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W
hen Eric, an 18-year-old who lives in San Francisco, wants to get some Vicodin (hydroco doneacetaminophen), it's a simple matter. "I can get prescription drugs from different places and don't ever have to see a doctor," he explained. "I have friends whose parents are pill addicts, and we 'borrow' from them. Other times I have friends who have ailments who get lots of pills and sell them for cheap. As long as prescription pills are taken right, they're much safer than street drugs." Eric's habits reflect an emerging pattern in drug use by teenagers: illicit street drugs such as "ecstasy" (3,4-methylenedioxymethamphetamine) and cocaine are decreasing in popularity, whereas the nonmedical use of certain prescription drugs is on the rise. These findings were reported in the Monitoring the Future survey, which is sponsored by the National Institute on Drug Abuse and designed and conducted by researchers at the University of Michigan. 1 The study, which began in 1975, annually surveys a nationally representative sample of about 50,000 students in 400 public and private secondary schools in the United States.
Overall, the proportion of teens who reported having used any illicit drug during the previous year has dropped by more than a third among 8th graders and by about 10 percent among 12th graders since the peaks reported in the mid-to-late 1990s, according to the 2005 survey. Alcohol use and cigarette smoking among teens are now at historic lows. In contrast, the number of high-school students who are abusing prescription pain relievers such as oxycodone (OxyContin), a potent and highly addictive opiate, or sedatives is on the rise. 
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To the Editor: We participated in the Drug Safety and Risk Management Advisory Committee, which was convened on February 9, 2006, to produce recommendations to the FDA about how best to study the rare occurrences of cardiovascular adverse events associated with medications used in the treatment of ADHD, including methylphenidate, amphetamine products, and atomoxetine. 1 We are concerned that a vote for a black-box warning was called without a discussion of content or language for such a warning; that the discussion did not thoroughly explore the risk associated with these medications for adults and children but implied that the risk might be higher for adults than for children; that recommendations about how best to convey the risk to children, adults, and families were not addressed;
and that the concern about the increased use of these medications was confused with concern about the actual risk.
We also participated in the Pediatric Advisory Committee, which was convened on March 22, 2006, to discuss how families and physicians might best be informed of the risk associated with these medications.
The discussion, which lasted for 11 hours, was informed by presentations by 7 FDA epidemiologists and physicians, 41 speakers in the public forum, and 2 representatives of pharmaceutical companies.
The Pediatric Advisory Committee recommended that the FDA include warnings, in the``highlights´´section of the newly formatted labeling, that children with structural heart defects, cardiomyopathy, or heart-rhythm disturbances may be at risk for adverse cardiac events, including sudden death; that children with symptoms of psychosis and mania are at risk for adverse neuropsychiatric events; and that children require follow-up visits and the monitoring of blood pressure, pulse, and growth measures 2,3 ( Table 1) . None of the committee members, when asked directly by FDA officials, said that a black-box warning was warranted.
The committee further recommended that the FDA -with input from professional, private, and public groups -design a guide for parents and physicians that would explain the risks of these medications in readily accessible language, modeled on successful guides used to inform parents about vaccinations for children.
We are impressed that the process of the March 22 meeting of the Pediatric Advisory Committee allowed for the airing of highly disparate and often passionate views regarding these issues. This process facilitated a frank and productive discussion by patients, family members, pediatricians, cardiologists, pharmacologists, child psychiatrists, and epidemiologists in a transparent, respectful, and public forum. and questions for the committee did not allow for the possibility of enhanced warnings. 2 The committee chose an independent course of action after reviewing data regarding adverse events, including cases of sudden death, and concluded that a warning was needed. These cases included that of a 13-year-old boy who died within one hour after receiving the first dose of mixed amphetamine salts; the boy was found to have had hypertrophic cardiomyopathy on autopsy. 2 Advisory committees never specify the language of such warnings, which is the responsibility of the FDA. I believe that the appearance of information in the``highlights´´section of the drug label will have virtually no effect on prescribing practices. Even a boxed warning has been shown to have a minimal effect on the inappropriate use of drugs. 3 The table included with this letter is highly misleading. Many studies have demonstrated that only 1 to 10 percent of serious adverse events are reported to the FDA through the Adverse Event Reporting
System. Accordingly, any calculation of an incidence rate for adverse events from such data is considered unreliable by FDA drug-safety staff, even for pediatric patients. 4 Both letters seem to ignore a fundamental fact that increasing heart rate and blood pressure 5 New England Journal of Medicine deemed sufficiently risky that the FDA has recommended banning these agents to protect the public health.
Wojnowski expresses concern about the increase in the use of stimulants by a factor of 20 in Germany but points out that such use in the United States is still 8 to 10 times as high. I share his concern.
The figure that appeared in my Perspective article shows an incorrect structure for epinephrine, which lacks the nonmethylated amine that is pictured. In addition, pseudoephedrine is an epimer of ephedrine, not an enantiomer, as described on page 1447.
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